Safety and Tolerability of the First IV Dosing of SLV338 in Healthy Volunteers

Solvay

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: SLV338

Study type: Interventional

Funder types: Industry

Identifiers

NCT00885989

2008-006753-40

S338.1.002

Details and patient eligibility

About

This study will investigate the safety and tolerability of the first IV dosing of SLV338 in healthy volunteers.

Enrollment: 42 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy

Exclusion criteria

• not healthy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

42 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: SLV338

2

Placebo Comparator group

Treatment:

Drug: Placebo